Valneva (VALN) Q1 2026 earnings review
Core Business Deteriorates, Forcing Drastic Restructuring Ahead of Lyme Data
Valneva’s Q1 results reveal a commercial portfolio under severe pressure. Total revenue plummeted 37% YoY to €30.9 million, and net loss significantly widened to €32.1 million. Management downgraded its 2026 revenue guidance, citing 'emerging adverse geopolitical trends' impacting travel vaccine uptake. With gross margins compressing across flagship products IXIARO and DUKORAL, and the IXCHIQ launch continuing to stall, management is taking drastic survival action: cutting the global workforce by 10-15% to slash operating expenses by roughly 30%. The successful >70% efficacy readout of the Phase 3 Lyme disease vaccine remains the company's ultimate lifeline, but Valneva must aggressively cut costs to ensure it survives to commercialize it.
🐂 Bull Case
The Phase 3 VALOR trial for the VLA15 Lyme vaccine showed >70% efficacy with no safety concerns. With Pfizer planning regulatory submissions, the path to major milestones and royalties is de-risked.
Slashing 10-15% of the workforce to cut OpEx by 25-35% in 2026 proves management is willing to take painful steps to preserve the €142M cash runway (including the recent raise) until the Lyme approval.
🐻 Bear Case
First-quarter sales missed expectations, margins were crushed by facility transfer costs, and geopolitical headwinds are shrinking the travel market. The core business cannot currently sustain the company.
The Chikungunya vaccine generated just €1.6M in sales with negative gross margins. The strategic pivot to LMIC markets is failing to offset the botched travel segment launch.
⚖️ Verdict: 🔴
Bearish. While the clinical success of the Lyme vaccine is a massive long-term win, the core commercial business is deteriorating much faster than anticipated. Margins are collapsing and guidance was cut, forcing a desperate restructuring to maintain the cash runway.
Key Themes
Margin Collapse in Core Portfolio
Gross margins across the core portfolio deteriorated sharply. IXIARO dropped from 72.6% to 50.8%, and DUKORAL plunged from 52.2% to 33.6%. Management blamed higher manufacturing costs at the new Almeida facility in Scotland, standard cost adjustments, and batch write-offs. If the new facility structurally increases the fixed-cost base, a return to historical profitability is in jeopardy.
Restructuring to Stop the Bleeding
In response to the revenue drop, Valneva initiated a drastic restructuring plan: cutting its global workforce by 10-15%. This is expected to drive a massive 25-35% reduction in 2026 operating expenses compared to 2025. This pivot from expansion to survival mode is a necessary driver for preserving cash ahead of VLA15 commercialization.
Geopolitical Macro Headwinds
Management explicitly called out an 'emerging adverse trend in travel vaccine uptake across key markets, driven by geopolitical factors.' This macro pressure forced a €10 million downward revision to FY26 guidance, indicating that Valneva's reliance on discretionary travel vaccines is a major vulnerability in the current global climate.
IXCHIQ Launch Stalls Further
The Chikungunya vaccine continues to be a commercial disappointment. Sales nearly halved YoY to €1.6 million, and gross margins were actually negative due to cancellation fees for external manufacturing following lower-than-anticipated sales. The ongoing pilot vaccination campaign in Brazil highlights the pivot to endemic markets, but the financial return remains elusive.
VLA15 Lyme Vaccine Crosses the Finish Line
The Phase 3 VALOR trial achieved its primary endpoint, demonstrating >70% efficacy in preventing Lyme disease with no safety concerns. With Pfizer now preparing regulatory submissions, this asset represents the company's singular transformational catalyst and bridge to long-term profitability.
Other KPIs
Despite a massive €32.1M net loss, operating cash burn was almost entirely offset, improving from €8.1M in 25Q1. This was driven by significantly lower net working capital requirements, showing management is actively squeezing the balance sheet to preserve liquidity.
Stable compared to €109.7M at the end of 2025. Notably, this figure excludes €37.0M in gross proceeds from a successful reserved offering completed in April 2026. Combined liquidity sits around ~€142M, which provides critical runway through the Lyme vaccine regulatory process.
Down from €27.5M in the prior year. The decline was primarily attributed to the phasing of deliveries to the U.S. Department of Defense. Management noted deliveries will continue in 2026 under the new contract.
Guidance
Decelerating. Lowered by €10M from the initial €155 - €170M range, and represents a decline versus FY25's €174.7M actuals. The drop is due to both geopolitical travel headwinds and the planned phase-out of third-party product sales.
Decelerating. Revised downward from €145 - €160 million. Represents a contraction from FY25's ~€158M product sales, reflecting the harsh reality of the current travel vaccine market.
Accelerating cost controls. Driven by a 10-15% global workforce reduction, this guidance confirms a massive strategic shift toward capital preservation in the face of declining sales.
Key Questions
Geopolitical Specifics
You cited 'geopolitical factors' causing an adverse trend in travel vaccine uptake. Which specific regions or routes are seeing the sharpest declines, and do you view this as a permanent market contraction or a temporary dip?
Almeida Facility Margins
With IXIARO and DUKORAL margins collapsing due in part to the Almeida facility transfer, what is the timeline for margins to normalize, and will the new facility structurally cap peak gross margins below historical ~70% levels?
IXCHIQ ROI Threshold
IXCHIQ generated negative gross margins and only €1.6M in sales. At what point do you halt commercial investment in the travel segment entirely to stop the bleeding, and rely solely on CEPI-funded LMIC programs?
Restructuring Depth
You are cutting 10-15% of your workforce to reduce OpEx by 25-35%. Which specific divisions (R&D vs Commercial) are taking the brunt of these cuts, and does this impact your readiness to launch VLA15 or advance S4V2?